As biopharma products are moving from niche to mainstream, the industry is facing a paradigm shift in cost, quality, complexity, and scale—creating opportunities to develop new and different technologies and operating models. Achieving the next phase of the industry potential will require a further revolution, not only in the laboratory but also in strategy, technology, and operations. Decisions made today will affect companies' competitive positions years or even decades into the future.
From science to operations: Questions, choices and strategies for success in biopharma
| Book Excerpt